The FDA’s clunky launch of Elsa, an AI tool to increase efficiency, has sparked concern from agency employees and outside ...

FDA staff tested Elsa on Monday with questions about FDA-approved products or other public information, only to find that it provided summaries that were either completely or partially wrong.

The FDA is using Elsa to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations and identify high-priority inspection targets. The Food and Drug Administration ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The FDA plans to roll out its new AI tool, called Elsa ...

FDA claims victory with "Elsa" AI tool launch, but insiders call it half-baked Employees say FDA's Elsa launch prioritized optics over usability By Cal Jeffrey June 5, 2025, 13:39.

The U.S. FDA announced this week that it deployed a generative AI tool called ELSA, now in use by staff across the agency, several weeks ahead of its original schedule.

Just a few weeks ago, Health and Human Services Secretary Robert F. Kennedy Jr. sat in front of Congress and confidently promised to “do more with less” by integrating artificial intelligence deeply ...

On June 2, the FDA dropped the other shoe, saying it had launched a generative AI tool called “Elsa” to help scientific reviewers and investigators work more efficiently.

One new tool, named Elsa, is similar to ChatGPT and may help the FDA review safety data, summarize reports and flag which drug or food facilities need inspection, The New York Times reported.

The FDA will plan to focus Elsa’s scope on administrative tasks such as summarizing documents and data extraction. This is the right approach, according to Panna Sharma, CEO and president of ...